NASDAQ:SPPI Spectrum Pharmaceuticals - SPPI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Spectrum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.54 -0.03 (-5.11%) (As of 01/30/2023 04:04 PM ET) Add Compare Share Share Today's Range$0.54▼$0.5850-Day Range$0.32▼$0.6052-Week Range$0.32▼$1.57Volume1.04 million shsAverage Volume1.35 million shsMarket Capitalization$101.63 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Spectrum Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside454.5% Upside$3.00 Price TargetShort InterestHealthy2.73% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.79Based on 6 Articles This WeekInsider TradingAcquiring Shares$22,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.48) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.45 out of 5 starsMedical Sector195th out of 1,049 stocksPharmaceutical Preparations Industry93rd out of 514 stocks 3.3 Analyst's Opinion Consensus RatingSpectrum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Spectrum Pharmaceuticals has a forecasted upside of 454.5% from its current price of $0.54.Amount of Analyst CoverageSpectrum Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.73% of the outstanding shares of Spectrum Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSpectrum Pharmaceuticals has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spectrum Pharmaceuticals has recently decreased by 13.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpectrum Pharmaceuticals does not currently pay a dividend.Dividend GrowthSpectrum Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSpectrum Pharmaceuticals has received a 74.89% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Spectrum Pharmaceuticals is -0.75. Previous Next 2.1 News and Social Media Coverage News SentimentSpectrum Pharmaceuticals has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Spectrum Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for SPPI on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Spectrum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spectrum Pharmaceuticals insiders have bought 147.44% more of their company's stock than they have sold. Specifically, they have bought $22,500.00 in company stock and sold $9,093.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of Spectrum Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 27.95% of the stock of Spectrum Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Spectrum Pharmaceuticals are expected to grow in the coming year, from ($0.48) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spectrum Pharmaceuticals is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spectrum Pharmaceuticals is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpectrum Pharmaceuticals has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Spectrum Pharmaceuticals (NASDAQ:SPPI) StockSpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.Read More Receive SPPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SPPI Stock News HeadlinesJanuary 30, 2023 | benzinga.comFRIDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 27, 2023 | benzinga.com7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 30, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 26, 2023 | finance.yahoo.comSpectrum Pharmaceuticals Announces New Employment Inducement Grant for Commercial StaffJanuary 25, 2023 | benzinga.comCLASS ACTION UPDATE for SPPI, NBEVQ and IBM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersJanuary 25, 2023 | wsj.comSpectrum Shareholder NoticeJanuary 18, 2023 | benzinga.comCLASS ACTION UPDATE for GNRC, SPPI and AVYA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersJanuary 17, 2023 | benzinga.comCLASS ACTION UPDATE for CURV, SPPI and FXLV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersJanuary 30, 2023 | Investing Trends (Ad)Solar Industry at Start of Long Bull Run?The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.January 4, 2023 | finance.yahoo.comSpectrum Pharmaceuticals Announces Management ChangesDecember 27, 2022 | benzinga.comCLASS ACTION UPDATE for SPPI, VERU and SGLY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersDecember 20, 2022 | wsj.comKaplan Fox Reminds Investors with Losses in Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) of Upcoming Lead Plaintiff DeadlineDecember 20, 2022 | wsj.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmDecember 16, 2022 | benzinga.comSPPI LAWSUIT ALERT: Levi & Korsinsky Notifies Spectrum Pharmaceuticals, Inc. Investors Of a Class Action Lawsuit and Upcoming DeadlineDecember 16, 2022 | benzinga.comCLASS ACTION UPDATE for GPS, SPPI and NEO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersDecember 16, 2022 | benzinga.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmDecember 12, 2022 | benzinga.comCLASS ACTION UPDATE for TSP, SPPI and NEO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersDecember 9, 2022 | benzinga.comNational Law Firm Investigating Spectrum Pharmaceuticals, Inc. Over Alleged False/Misleading Statements Regarding New Drug ApplicationDecember 9, 2022 | benzinga.comNational Law Firm Investigating Spectrum Pharmaceuticals, Inc. Over Alleged False/Misleading Statements Regarding New Drug ApplicationDecember 9, 2022 | wsj.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmDecember 8, 2022 | wsj.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmDecember 7, 2022 | benzinga.comCLASS ACTION UPDATE for SQ, ARGO and SPPI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersDecember 6, 2022 | benzinga.comBronstein, Gewirtz & Grossman, LLC Notifies Spectrum Pharmaceuticals, Inc. (SPPI) Investors of Class Action and to Actively ParticipateDecember 6, 2022 | finance.yahoo.comSpectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth FactorsDecember 5, 2022 | finance.yahoo.comSpectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial StaffDecember 3, 2022 | wsj.comBragar Eagel & Squire, P.C. Is Investigating Spectrum, F45 Training, PROG, and Fox and Encourages Investors to Contact the FirmNovember 29, 2022 | bizjournals.comBoston cancer firm axes 75% of staff after FDA rejectionSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SPPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SPPI Company Calendar Last Earnings11/10/2022Today1/30/2023Next Earnings (Estimated)3/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SPPI CUSIP84763A10 CIK831547 Webwww.sppirx.com Phone(702) 835-6300Fax702-260-7405Employees163Year Founded2002Price Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+455.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-158,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-246.66% Return on Assets-103.55% Debt Debt-to-Equity RatioN/A Current Ratio2.28 Quick Ratio2.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book1.86Miscellaneous Outstanding Shares188,160,000Free Float183,084,000Market Cap$101.63 million OptionableOptionable Beta2.03 Social Links Key ExecutivesMr. Thomas J. Riga (Age 48)Pres, CEO & Director Comp: $1.02MMs. Nora E. Brennan (Age 54)Exec. VP & Chief Financial Officer Comp: $54.17kMr. Keith M. McGahan J.D. (Age 47)L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec. Comp: $851.73kDr. Francois J. Lebel FRCPC (Age 71)M.D., Exec. VP & Chief Medical Officer Comp: $917.96kMr. Bimal R. ShahVP of Corp. & Bus. Devel.Mr. Michael A. GrabowExec. VP & Chief Bus. OfficerDr. Lyndah K. Dreiling M.B.A.M.D., Sr. VP of Clinical Devel.More ExecutivesKey CompetitorsFortress BiotechNASDAQ:FBIOVerastemNASDAQ:VSTMMerrimack PharmaceuticalsNASDAQ:MACKInfinity PharmaceuticalsNASDAQ:INFIBolt BiotherapeuticsNASDAQ:BOLTView All CompetitorsInsiders & InstitutionsThomas J RigaSold 23,929 sharesTotal: $9,093.02 ($0.38/share)Jeff L VacircaBought 50,000 shares on 11/30/2022Total: $22,500.00 ($0.45/share)Jane Street Group LLCBought 113,300 shares on 11/16/2022Ownership: 0.000%Vanguard Group Inc.Sold 161,556 shares on 11/15/2022Ownership: 4.606%State Street CorpSold 98,200 shares on 11/15/2022Ownership: 0.331%View All Insider TransactionsView All Institutional Transactions SPPI Stock - Frequently Asked Questions Should I buy or sell Spectrum Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SPPI shares. View SPPI analyst ratings or view top-rated stocks. What is Spectrum Pharmaceuticals' stock price forecast for 2023? 4 brokerages have issued 12-month price objectives for Spectrum Pharmaceuticals' stock. Their SPPI share price forecasts range from $1.00 to $4.00. On average, they predict the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 426.3% from the stock's current price. View analysts price targets for SPPI or view top-rated stocks among Wall Street analysts. How have SPPI shares performed in 2023? Spectrum Pharmaceuticals' stock was trading at $0.3685 on January 1st, 2023. Since then, SPPI stock has increased by 54.7% and is now trading at $0.57. View the best growth stocks for 2023 here. When is Spectrum Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023. View our SPPI earnings forecast. How were Spectrum Pharmaceuticals' earnings last quarter? Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings results on Thursday, November, 10th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.03. What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO? 2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Spectrum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE). What is Spectrum Pharmaceuticals' stock symbol? Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI." How do I buy shares of Spectrum Pharmaceuticals? Shares of SPPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Spectrum Pharmaceuticals' stock price today? One share of SPPI stock can currently be purchased for approximately $0.57. How much money does Spectrum Pharmaceuticals make? Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $107.25 million. The biotechnology company earns $-158,630,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. How many employees does Spectrum Pharmaceuticals have? The company employs 163 workers across the globe. How can I contact Spectrum Pharmaceuticals? Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (702) 835-6300, via email at ir@sppirx.com, or via fax at 702-260-7405. This page (NASDAQ:SPPI) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.